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Zusammenfassung
Die 43. jährliche ASCO-Tagung fand dieses Jahr vom 1.
bis 5. Juni im McCormick Place, Chicago, IL, USA statt. In
diesem Jahr stand die Tagung unter dem Motto: «Trans-
lating Research into Practice» und präsentierte 445 Ab-
strakts über translationale Forschung zusätzlich zu den
über 2000 Abstrakts über Chirurgie, Strahlentherapie,
Chemotherapie, endokrine und zielgerichtete Therapie
(alle Beiträge sind ab dem 1. September 2007 öffentlich
zugänglich unter www.asco.org). Dieser kurze Über-
sichtsartikel legt seinen Schwerpunkt auf die beiden
wichtigen Vortragssitzungen über Brustkrebs und ver-
sucht die präsentierten Daten mit einem kurzen Fazit zu
ihrer klinischen Relevanz zu kommentieren. Insgesamt
bestätigten die in diesem Jahr gezeigten Daten zum
Thema Brustkrebs die derzeitigen Therapiestandards und
zeigten neue Therapieoptionen mit zielgerichteten Sub-
stanzen auf. Im nächsten Jahr wird die ASCO-Tagung
wieder in Chicago abgehalten (30. Mai bis 3. Juni 2008).
Diejenigen, denen die Wartezeit bis dahin zu lang ist,
können sich in diesem Jahr erstmalig auf einem speziel-
len ASCO Brustkrebs-Symposium (7. bis 8.September
2007) in San Francisco, CA, USA, informieren. Ob dieser
Kongress eine neue Tradition spezialisierter ASCO Brust-
krebs-Jahrestagungen starten wird und wie sich dies
dann auf das alljährliche San Antonio Breast Cancer
Symposium im Dezember auswirken wird, bleibt abzu-
warten.
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Summary
The 43rd ASCO Annual Meeting took place from June
1–5, 2007 at McCormick Place in Chicago, IL, USA. This
year’s meeting had the special theme of ‘Translating Re-
search into Practice’, particularly featuring 445 abstracts
on translational research in addition to approximately
2,000 abstracts presented on subjects like surgery, radia-
tion therapy, chemotherapy, endocrine therapy, and tar-
geted therapies. This short summary will focus on the
two important breast cancer oral presentation sessions
only, and will try to comment on the presented data with
regard to their immediate impact on clinical practice.
Many more research results regarding breast cancer
were presented (all presentations will be available to the
public from September 1, 2007 at www.asco.org). In gen-
eral, breast cancer data presented at this year’s ASCO
Annual Meeting confirmed current standards, and intro-
duced promising new substances which may soon enter
clinical practice. The 44th ASCO Annual Meeting will
again be held in Chicago from May 30 to June 3, 2008.
Those who do not want to wait another year may visit
ASCO’s first special Breast Cancer Symposium taking
place September 7–8, 2007 in San Francisco, CA, USA.
Whether this meeting will start a new tradition of a spe-
cialized ASCO breast cancer symposium, and how this
development will eventually will impact on the regular
San Antonio Breast Cancer Symposium in December,
only time will tell.
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Introduction
The 43rd ASCO Annual Meeting took place from June 1–5,
2007 at McCormick Place in Chicago, IL, USA. This year’s
meeting had the special theme of ‘Translating Research into
Practice’, particularly featuring 445 abstracts on translational
research in addition to approximately 2,000 abstracts present-
ed on subjects like surgery, radiation therapy, chemotherapy,
endocrine therapy, and targeted therapies. This short summary
will focus on the important breast cancer oral presentation
sessions only, and will try to comment on the presented data
with regard to their immediate impact on clinical practice.
Adjuvant Therapy
The 2007 adjuvant breast cancer oral presentation session was
chaired by Jenny Chang (Baylor College, Houston, TX, USA)
and Mark Pegram (UCLA, Los Angeles, CA, USA). There
were no talks on endocrine therapy trials in this session.
Edith Perez presented an update of the joint analysis of the
NCCTG9831 and NSABP-B31 adjuvant trastuzumab trials
(abstract 512) which included 3,968 patients, 619 events, and
258 deaths. After a longer median follow-up of now 2.9 years,
the previously observed clinical benefit of 1 year of adjuvant
trastuzumab remains stable in the intent-to-treat analysis de-
spite a total crossover of 20.9% of patients (n = 413) from the
control arm to trastuzumab therapy: The estimated relapse-
free survival after 4 years was 85.9 vs. 73.1%, with an adjusted
hazard ratio (HR) of 0.48 (95% confidence interval (CI)
0.41–0.57), p < 0.00001. No survival benefit could be seen in the
very small subgroup of node-negative patients (approximately
7%), yet all other clinically relevant subgroups do benefit from
trastuzumab therapy. The estimated overall survival (OS) after
4 years was 92.6 vs. 89.4%, with a HR of 0.65 (95% CI
0.51–0.84), p = 0.0007. The highest event rates (including recur-
rent disease, contralateral breast cancer, second primary,
death) were seen between years 2–3 in the trastuzumab as well
as in the control arm with a sharp decline after year 3 in both
arms. In NCCTG9831, total cardiac complications were signifi-
cantly different between the 2 study arms (trastuzumab yes/no)
with 2.5 vs. 0.2% at 3 years. In a late breaking abstract (LBA
513), Priva Rastogi presented an update of the cardiac safety
data of NSABP B-31 showing that the overall congestive heart
failure (CHF) rate has remained rather stable over time with
now 3.8% (vs. 0.9%) after 5 years, compared to 4.1% (vs.
0.8%) after 3 years (data shown at ASCO 2005). There are
now a total of 35 patients with CHF (no deaths) vs. 6 patients
in the control arm (1 death). In multivariate analysis, the major
risk factors for developing cardiac dysfunction were older age,
low baseline left ventricular ejection fraction (LVEF), and hy-
pertensive medication. In conclusion, the survival advantage
gained by 1 year of adjuvant trastuzumab remains strong and
stable after longer follow-up. Optimal therapy duration and se-
quence for clinical routine remain open questions. With regard
to cardiotoxicity, starting trastuzumab therapy parallel to tax-
ane-containing adjuvant chemotherapy seems to be associated
with a CHF rate of approximately 4%. Particularly at risk are
women aged 50 or older, those on antihypertensive medica-
tion, those with a LVEF < 55 at baseline or after doxorubicin/
cyclophosphamide (AC) chemotherapy.
Three talks in the main session, addressed the adjuvant use of
taxanes: A pooled analysis of 2 adjuvant docetaxel trials,
BCIRG001 and PACS 01 (n = 3,490), showed that the superi-
ority regarding disease-free survival (DFS) and OS of doce-
taxel-containing adjuvant chemotherapy compared to a stan-
dard anthracycline regimen is independent of the estrogen re-
ceptor (ER) status as well as the degree of ER expression
(Andre et al., abstract 537). The E1199 trial (n = 5,052) which
had already been presented at the San Antonio Breast Cancer
Symposium (SABCS) 2005 compared the two taxanes, pacli-
taxel and docetaxel, given weekly or every 3 weeks (after 4 cy-
cles of AC) without being able to show a significant efficacy
difference in relation to type of taxane or schedule (Sparano
et al., abstract 516). The best 5-year DFS rates were achieved
by weekly paclitaxel (81.5%) and 3-weekly docetaxel (81.2%).
Accordingly, compared to 3-weekly paclitaxel, the largest re-
lapse risk reductions (approximately 25%) were reached by
weekly paclitaxel or 3-weekly docetaxel. The 5-year update
(Loesch et al., abstract 517) of the phase III trial comparing
adriamycin/paclitaxel followed by weekly paclitaxel (AP→P)
vs. the Henderson regimen (AC→P) did not confirm the DFS
advantage observed in the 3-year follow-up which was pre-
sented at SABCS 2004. In this second analysis, no benefit was
found regarding 5-year DFS (p = 0.38), and only a borderline
OS advantage for AP→P with 90 vs. 87% at 5 years (HR 0.76;
p = 0.04). Triple negative patients did seem to derive a partic-
ular benefit from AP→P as unplanned subgroup analyses
showed. In conclusion, adjuvant taxane-containing chemo-
therapy remains a standard for node-positive patients regard-
less of the hormone receptor status. In a sequence of AC
followed by a taxane, both weekly paclitaxel and 3-weekly
docetaxel seem to be more effective than 3-weekly paclitaxel
or weekly docetaxel.
Therapy of Metastatic Breast Cancer
The 2007 metastatic breast cancer oral presentation session
was chaired by Antonio Wolff (Sidney Kimmel Comprehen-
sive Cancer Center at Johns Hopkins, Baltimore, MD, USA)
and Nadia Harbeck (Technical University of Munich, Ger-
many). A number of talks addressed new combinations, in par-
ticular those of a chemotherapy regimen with targeted drugs.
Mark Pegram (LBA 1008) showed the first OS analysis of
BCIRG 007 (i.e. docetaxel100/trastuzumab (TH) vs. docetax-
el75/carboplatin AUC5/trastuzumab (TCH)) for which the
DFS had already been presented at ASCO 2006. In first line
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therapy for metastatic breast cancer, there is no survival ad-
vantage of TCH vs. TH after a median follow-up of 39 months
(n = 263): The median OS TH vs. TCH was 36.40 vs. 36.57
months (p = 0.65). Neutropenic infections occurred at a rate of
16.8% (TH) vs. 9.2% (TCH) (p = 0.097) with no significant
difference in the febrile neutropenia rate and 2 septic deaths
(both with TCH). The rate of thrombocytopenia was 2.3%
(TH) vs. 15.3% (TCH) (p < 0.01). In conclusion, in contrast to
the adjuvant setting, the TCH regimen does not offer any
substantial advantage (vs. TH) in the metastatic setting, and
should thus not be considered a standard regimen in this ther-
apy indication.
Angelo di Leo (abstract 1011) presented the phase III trial of
first line therapy with paclitaxel (P) vs. paclitaxel/lapatinib
(PL) in HER2-negative disease (n = 580). In blinded central
re-evaluation, 19% of patients in the PL and 15% in the P arm
had HER2-positive disease. Adverse events (e.g. rash, diar-
rhea, and mucositis) were higher in the PL arm. Among seri-
ous adverse events (SAE), only diarrhea was significantly
higher (8 vs. <0.1%; p < 0.0001) in the PL arm. SAE-related
deaths were more common in the combination arm (2.7 vs.
0.6%). As expected, the management of side effects, in partic-
ular diarrhea, improved over time. In the total patient group,
there was no survival (time to progression (TTP), OS) advan-
tage for the addition of lapatinib to paclitaxel chemotherapy.
Yet, in HER2-positive disease, there was an advantage for PL
regarding response rate (60 vs. 36%; p = 0.027), duration of
response (median 7.4 vs. 5.5 months), and TTP (median 8.1
vs. 5.8 months; p = 0.011). OS did not differ significantly in
HER2-positive disease. In conclusion, clinical effectiveness of
the multikinase inhibitor lapatinib seems to be limited to
HER2-positive disease even though its mechanism of action
does suggest additional HER2-independent efficacy. This un-
derlines the importance of appropriate patient selection and
target determination for targeted therapy trials.
The EGF 105084 trial (Lin et al., abstract 1012) evaluated
lapatinib monotherapy (750 mg twice daily) in patients with
HER2-positive brain metastasis after trastuzumab and cranial
radiotherapy (n = 241). In 19% of patients, a maximum tumor
volumetric reduction of the central nervous lesions of at least
20%, and in 7% of patients of at least 50%, was observed.
Median progression-free survival (PFS) under lapatinib
monotherapy was 15.1 weeks with a 6-month PFS rate of 22%.
An extension period of this study with lapatinib/capecitabine
is still being evaluated, but early response data suggest that
the combination may be more effective (20% achieving ≥50%
volumetric reduction and 40% ≥20%). In conclusion, lapatinib
does have activity as a monotherapy in central nervous metas-
tasis which is of course limited in the very advanced clinical
situation evaluated in this trial. So far lapatinib monotherapy
should therefore only be used in individual HER2 breast can-
cer cases with brain metastasis.
E. Alba (abstract 1007) presented the GEICAM 2001–01
phase III study looking at the benefit of a maintenance therapy
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with pegylated liposomal doxorubicin (PLD 40 mg/m2 q28)
after first line chemotherapy with an anthracycline-taxane se-
quence. Of the 288 patients initially registered, 155 with com-
plete remission (CR), partial remission (PR), or stable disease
(SD) were able to be randomized after induction chemothera-
py. 50% completed all planned 6 cycles of PLD maintenance
therapy. PLD maintenance significantly improved TTP after
randomization (median 8.4 vs. 5.1 months; p = 0.0006), and
after the initial induction treatment (median 13.2 vs. 10.2
months; p = 0.0005) with manageable toxicity. In conclusion,
maintenance therapy with 6 cycles of PLD is feasible after an
anthracycline-taxane induction chemotherapy. It prolongs TTP
by approximately 3 months with progressions being avoided
while on maintenance chemotherapy. Yet, OS data are still
lacking thus making maintenance therapy an option only in in-
dividual patients for whom progression needs to be avoided
and an endocrine maintenance therapy is not available.
The XCALIBr trial looked at safety and efficacy of first line
capecitabine (1,000 mg/m2 twice daily) and bevacizumab
(Sledge et al., abstract 1013) with a median follow-up of 12.9
months being reported at ASCO this year. In 106 HER2-neg-
ative tumors, the overall response rate (ORR: CR + PR) was
38% with the combination being well tolerated. Median TTP
of 5.7 months was significantly longer for the combination
than estimated for capecitabine monotherapy (4 months). Pa-
tients with ER-positive disease derived particular benefit with
a median TTP of 8.9 vs. 4.0 months for ER-negative disease.
In conclusion, capecitabine/bevacizumab is an active combina-
tion in first line therapy which adds another first line option to
the registered paclitaxel/bevacizumab combination. Whether
the particular benefit in ER-positive disease is bevacizumab-
related or due to an endocrine impact on the capecitabine me-
tabolism, cannot be decided at this point. In addition, data
from the pre-defined second line chemotherapy + bevacizu-
mab study part will help to clarify therapy options after pro-
gression on bevacizumab and first line chemotherapy.
Conclusion
Obviously, many more research results regarding breast can-
cer were presented (all presentations will be available to the
public from September 1, 2007 at www.asco.org). In general,
breast cancer data presented at this year’s ASCO Annual
Meeting confirmed current standards and introduced promis-
ing new substances which may soon enter clinical practice. The
44th ASCO Annual Meeting will again be held in Chicago
from May 30 to June 3, 2008. Those who do not want to wait
another year may visit ASCO’s first special Breast Cancer
Symposium taking place September 7–8, 2007 in San Francis-
co, CA, USA. Whether this meeting will start a new tradition
of a specialized ASCO breast cancer symposium, and how this
development will eventually will impact on the regular
SABCS in December, only time will tell.
241_243_harbeck  22.08.2007  9:19 Uhr  Seite 243
